What is the share price of Biogen Pharmachem Industries Ltd (BIOGEN) today?
The share price of BIOGEN as on 18th March 2025 is ₹1. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Biogen Pharmachem Industries Ltd (BIOGEN) share?
The past returns of Biogen Pharmachem Industries Ltd (BIOGEN) share are- Past 1 week: -1.98%
- Past 1 month: 5.32%
- Past 3 months: -20.16%
- Past 6 months: -24.43%
- Past 1 year: -13.16%
- Past 3 years: -38.51%
- Past 5 years: 421.05%
What are the peers or stocks similar to Biogen Pharmachem Industries Ltd (BIOGEN)?
The peers or stocks similar to Biogen Pharmachem Industries Ltd (BIOGEN) include:What is the market cap of Biogen Pharmachem Industries Ltd (BIOGEN) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Biogen Pharmachem Industries Ltd (BIOGEN) is ₹64.61 Cr as of 18th March 2025.What is the 52 week high and low of Biogen Pharmachem Industries Ltd (BIOGEN) share?
The 52-week high of Biogen Pharmachem Industries Ltd (BIOGEN) is ₹1.76 and the 52-week low is ₹0.92.What is the PE and PB ratio of Biogen Pharmachem Industries Ltd (BIOGEN) stock?
The P/E (price-to-earnings) ratio of Biogen Pharmachem Industries Ltd (BIOGEN) is 33.48. The P/B (price-to-book) ratio is 1.14.Which sector does Biogen Pharmachem Industries Ltd (BIOGEN) belong to?
Biogen Pharmachem Industries Ltd (BIOGEN) belongs to the Health Care sector & Biotechnology sub-sector.How to buy Biogen Pharmachem Industries Ltd (BIOGEN) shares?
You can directly buy Biogen Pharmachem Industries Ltd (BIOGEN) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Biogen Pharmachem Industries Ltd
BIOGENBiogen Pharmachem Industries Ltd
BIOGEN
Health CareBiotechnology
SmallcapWith a market cap of ₹64 cr, stock is ranked 3,266
High RiskStock is 3.63x as volatile as Nifty
1.001.01% (+0.01)
1.001.01% (+0.01)
Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -91.00 | 1.14 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 47.31 | 6.04 | 0.55% |
Forecast & Ratings
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Biogen Pharmachem Industries Ltd is currently inactive and seeking opportunities for operational engagement.
Peers
Compare with peersBIOCON
PE Ratio
39.04
1Y Return
32.95%
Buy Reco %
73.33
ONESOURCE
PE Ratio
-42.95
1Y Return
14.14%
Buy Reco %
—
SAILIFE
PE Ratio
177.15
1Y Return
7.82%
Buy Reco %
66.67
PANACEABIO
PE Ratio
-2,050.59
1Y Return
185.50%
Buy Reco %
—
3BBLACKBIO
PE Ratio
48.02
1Y Return
136.76%
Buy Reco %
—
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Annual Normal View
Income Statement
Annual Normal View
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.16 | 0.95 | 0.00 | 1.62 | 2.48 | 0.91 | 2.38 | 0.27 | ||||||||||
Raw Materials | 0.02 | — | — | — | — | — | — | — | — | 0.98 | ||||||||||
| Power & Fuel Cost | — | — | — | — | — | — | — | — | ||||||||||||
| Employee Cost | 0.01 | 0.03 | 0.04 | 0.04 | 0.01 | 0.05 | 0.17 | 0.08 | ||||||||||||
| Selling & Administrative Expenses | — | — | — | — | — | — | — | — | ||||||||||||
| Operating & Other expenses | 0.12 | 6.69 | 0.92 | 0.08 | 3.21 | 2.43 | 0.28 | 0.37 | ||||||||||||
EBITDA | -0.02 | -0.13 | -6.56 | -0.01 | -0.12 | -1.60 | 0.00 | 0.46 | 1.93 | -0.71 | ||||||||||
| Depreciation/Amortization | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||||||||
| PBIT | -0.02 | -0.13 | -6.56 | -0.01 | -0.12 | -1.60 | 0.00 | 0.46 | 1.93 | -0.71 | ||||||||||
| Interest & Other Items | — | — | — | — | — | — | — | — | — | — | ||||||||||
| PBT | -0.02 | -0.13 | -6.56 | -0.01 | -0.12 | -1.60 | 0.00 | 0.46 | 1.93 | -0.71 | ||||||||||
| Taxes & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||||||||
| Net Income | -0.02 | -0.13 | -6.56 | -0.01 | -0.12 | -1.60 | 0.00 | 0.46 | 1.93 | -0.71 | ||||||||||
| EPS | -0.00 | -0.00 | -0.10 | -0.00 | -0.00 | -0.02 | 0.00 | 0.01 | 0.03 | -0.01 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
FY 2015
Annual report
PDFFY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2022
Annual report
PDFFY 2023
Annual report
PDFFY 2024
Annual report
PDFPeers & Comparison
Comparing 3 stocks from
Health CareBiotechnology
Compare valuation on Screener
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Biogen Pharmachem Industries Ltd | 33.48 | 1.14 | — |
| Biocon Ltd | 39.04 | 1.58 | 0.15% |
| Onesource Specialty Pharma Ltd | -42.95 | 42.46 | — |
| Sai Life Sciences Ltd | 177.15 | 15.04 | — |
Price Comparison
Compare BIOGEN with any stock or ETFCompare BIOGEN with any stock or ETF
BIOGEN
Shareholdings
Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
BIOGEN has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNews & Opinions
Articles & Videos
Earnings
Biogen Pharmachem Industries reports standalone net loss of Rs 0.31 crore in the December 2024 quarter
Net loss of Biogen Pharmachem Industries reported to Rs 0.31 crore in the quarter ended December 2024 as against net profit of Rs 0.06 crore during the previous quarter ended December 2023. There were no Sales reported in the quarter ended December 2024 and during the previous quarter ended December 2023.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Biogen Pharmachem Industries announces board meeting date
Biogen Pharmachem Industries will hold a meeting of the Board of Directors of the Company on 5 February 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Biogen Pharmachem Industries reports standalone net loss of Rs 1.00 crore in the September 2024 quarter
Net loss of Biogen Pharmachem Industries reported to Rs 1.00 crore in the quarter ended September 2024 as against net profit of Rs 0.72 crore during the previous quarter ended September 2023. There were no Sales reported in the quarter ended September 2024 and during the previous quarter ended September 2023.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Biogen Pharmachem Industries to announce Quarterly Result
Biogen Pharmachem Industries will hold a meeting of the Board of Directors of the Company on 13 November 2024.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Biogen Pharmachem Industries to convene AGM
Biogen Pharmachem Industries announced that the Annual General Meeting (AGM) of the company will be held on 28 September 2024.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Biogen Pharmachem Industries to hold AGM
Biogen Pharmachem Industries announced that the Annual General Meeting (AGM) of the company will be held on 28 September 2024.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Biogen Pharmachem Industries revises board meeting date
Biogen Pharmachem Industries has revised the meeting of the Board of Directors which was scheduled to be held on 9 August 2024. The meeting will now be held on 13 August 2024.Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Biogen Pharmachem Industries to conduct board meeting
Biogen Pharmachem Industries will hold a meeting of the Board of Directors of the Company on 9 August 2024.Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Biogen Pharmachem Industries reports standalone net loss of Rs 0.16 crore in the June 2024 quarter
Net loss of Biogen Pharmachem Industries reported to Rs 0.16 crore in the quarter ended June 2024 as against net profit of Rs 0.41 crore during the previous quarter ended June 2023. There were no Sales reported in the quarter ended June 2024 and during the previous quarter ended June 2023.Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Biogen Pharmachem Industries to conduct board meeting
Biogen Pharmachem Industries will hold a meeting of the Board of Directors of the Company on 1 August 2024.Powered by Capital Market - Live
7 months agoCapital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 20.16%, vs industry avg of 19.04%
Constant Market Share
Over the last 5 years, market share stayed at 0.01%